Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling of mouse lymphoma L5178Y cells treated with Taxol (Paclitaxel) ILSI-HESI Genotoxicity Study - Taxol

ABSTRACT: Mouse lymphoma L5178Y cells are treated with Taxol (Paclitaxel) [CAS:33069-62-4;CHEBI:7887] and harvested at 4 and 24 hours for analysis.

INSTRUMENT(S): (Make:Affymetrix Scanner,Model:)

ORGANISM(S): Mus musculus

SUBMITTER: Syril Pettit

PROVIDER: E-TOXM-9 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Toxicogenomics in risk assessment: an overview of an HESI collaborative research program.

Pennie William W Pettit Syril D SD Lord Peter G PG

Environmental health perspectives 20040301 4

The value of genomic approaches in hypothesis generation is being realized as a tool for understanding toxicity and consequently contributing to an assessment of drug and chemical safety. In 1999 the membership of the International Life Sciences Institute Health and Environmental Sciences Institute formed a committee to develop a collaborative scientific program to address issues, challenges, and opportunities afforded by the emerging field of toxicogenomics. Experts and advisors from academia a ...[more]

PMID: 15033589

Similar Datasets

Transcription profiling of mouse lymphoma L5178Y cells treated with Cisplatin - ILSI-HESI Genotoxicity Study - Cisplatin

Project description:Mouse lymphoma L5178Y cells are treated with Cisplatin [CAS:15663-27-1;CHEBI:27899] and harvested at 4 and 24 hours for analysis.

2004-02-13 | E-TOXM-4 | biostudies-arrayexpress

Transcription profiling of mouse lymphoma L5178Y cells treated with Hydroxyurea - ILSI-HESI Genotox Study - Hydroxyurea

Project description:Mouse lymphoma L5178Y cells are treated with Hydroxyurea [CAS:127-07-1;CHEBI:5816] and harvested at 4 and 24 hours for analysis.

2006-02-13 | E-TOXM-6 | biostudies-arrayexpress

Transcription profiling of mouse lymphoma L5178Y cells treated with Mitomycin C - ILSI-HESI Genotoxicity Study - Mitomycin

Project description:Mouse lymphoma L5178Y cells are treated with Mitomycin C [CAS:50-07-7;CHEBI:27504] and harvested at 4 and 24 hours for analysis.

2004-05-13 | E-TOXM-8 | biostudies-arrayexpress

Transcription profiling of Mouse lymphoma L5178Y cells treated with Benzo(a)pyrene diolepoxide I (BDPE) - ILSI-HESI Genotoxicity Study -BDPE

Project description:Mouse lymphoma L5178Y cells are treated with Benzo(a)pyrene diolepoxide I (BDPE) [CAS:58917-67-2;CHEBI:30614] and harvested at 4 and 24 hours for analysis.

2005-02-13 | E-TOXM-2 | biostudies-arrayexpress

Transcription profiling of mouse lymphoma L5178Y cells treated with Bleomycin- ILSI-HESI Genotoxicity Study - Bleomycin

Project description:Mouse lymphoma L5178Y cells are treated with Bleomycin [CAS:11056-06-7;CHEBI:3139] and harvested at 4 and 24 hours for analysis.

2004-06-13 | E-TOXM-3 | biostudies-arrayexpress

Transcription profiling of mouse lymphoma L5178Y cells treated with 4-NitroQuinoline N-Oxide (4-NQO) ILSI-HESI Genotoxicity Study - 4-NQO

Project description:Mouse lymphoma L5178Y cells are treated with 4-NitroQuinoline N-Oxide (4-NQO) [CAS:56-57-5;CHEBI:16907] and harvested at 4 and 24 hours for analysis.

2006-02-13 | E-TOXM-1 | biostudies-arrayexpress

Transcription profiling of mouse lymphoma L5178Y and Human TK6 cells treated with Methylmethane Sulfonate ILSI-HESI Genotoxicity Study - MMS

Project description:Mouse lymphoma L5178Y and Human TK6 cells are treated with Methylmethane Sulfonate [CAS:66-27-3;CHEBI:25255] and harvested a 4 and 24 hours for analysis.

2005-02-13 | E-TOXM-7 | biostudies-arrayexpress

Transcription profiling of mouse lymphoma L5178Y cells treated with EtoposideILSI-HESI Genotoxicity Study - Etoposide

Project description:Mouse lymphoma L5178Y cells are treated with Etoposide [CAS:33419-42-0;CHEBI:4911] and harvested a 4 and 24 hours for analysis.

2004-02-13 | E-TOXM-5 | biostudies-arrayexpress

Transcription profiling of mouse lymphoma L5178Y cells treated with Hydroxyurea

Project description:The multi-lab International Life Sciences Institute (ILSI) project on the application of genomics to risk assessment offered the unique opportunity to investigate the influence of variability within and between laboratories on identifying biologically relevant gene expression changes. We assessed the gene expression profiles of mouse lymphoma L5178Y cells treated with hydroxyurea (HU) in three independent studies from two different laboratories, Sanofi-Aventis and Procter and Gamble. Cells were dosed for 4 hr and harvested immediately at the end of the treatment or after a 20-hr recovery period. Cytotoxicity and genotoxicity were evaluated by standard assays. Statistical analysis of these data revealed that, while gene expression responses to HU treatment were markedly different at 4 hr vs. 24 hr, there was otherwise a consistent pattern of dose-response across the three studies. Therefore, the studies were merged and each time point was evaluated separately. At 4 hr, we identified 173 (P lt 0.0001) dose-responsive genes with a common trend in all three studies. These were mainly associated with the cell cycle, DNA repair and DNA metabolism, and in particular, the intra-S and G2/M phase checkpoints. At 24 hr, we identified 434 dose-responsive genes common across studies. These genes were involved in lymphocyte-specific activities and the activation of apoptosis via the caspase cascade. Our results show that despite inter-laboratory variability, combining the three studies in a single statistical analysis identifies more significantly-modulated genes than in any of the individual studies, due to improved statistical sensitivity. The genes identified in our study provide information that is relevant to HU biology.

2005-08-25 | E-TOXM-17 | biostudies-arrayexpress

A novel treatment for glioblastoma based on Taxol activation of PC1/3-depleted macrophages: evidence from a proteomic and functional study.

Project description:Tumor-associated macrophages contribute to tumor pathogenesis and represent an attractive therapeutic target. We report that the proprotein convertase PC1/3 inhibits the TLR4 Myd88-pathway induced in macrophages by the anti-cancer agent Taxol. Thus, PC1/3 knock-down in these cells exacerbates the TLR4 MyD88-dependent pathway triggered by Taxol. In PC1/3 knock-down macrophages, Taxol drives the secretion of pro-inflammatory cytokines, inhibits STAT3 signaling and counteracts tumor-supportive activities, thus inhibiting viability, growth and invasion of glioblastoma cells. Proteomic analyses indicate that their secretomes are characterized by a unique protein profile supporting a specific paracrine anti-tumoral effect. These findings unravel the potential value of a new therapeutic strategy combining PC1/3 inhibition and activation of the TLR4 MyD88-dependent pathway to switch intra-tumoral macrophages toward an anti-tumoral immunophenotype.

2018-03-19 | PXD004444 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data